July 2008 in “Journal of Intellectual Property Law & Practice” This ruling by the UK Court of Appeal allows patents for pharmaceuticals based on new dosing regimens and can override previous decisions to align with European Patent Office practices.
March 2016 in “Journal of Pharmacological Sciences” This discussion reviews the shift in pharmaceutical strategy towards evidence-based and structure-guided drug development, highlighting ongoing challenges and efforts in computer-aided drug design without presenting new clinical results.
May 2015 in “Journal of the American Academy of Dermatology” Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.
June 2026 in “Journal of cancer research updates” This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.
April 2012 in “Dermatology Times E-News” Finasteride must now warn about lasting sexual side effects.
1 citations
,
October 2025 in “Scientific Reports” This study reports that hedgehog pathway inhibitors, sonidegib and vismodegib, showed distinct adverse event patterns in real-world data, suggesting the need for further research to confirm these findings.
January 2015 in “Zurich Open Repository and Archive (University of Zurich)” This study found no significant difference in anagen rate improvement between the CYP-based dietary supplement and placebo in women over 60 with telogen effluvium, possibly due to variable patient inclusion related to hair growth seasonality.
59 citations
,
February 2003 in “Veterinary Dermatology” This narrative review discusses the use of cyclosporin for various skin diseases in small animals and notes minimal side effects at therapeutic doses, but reports no original clinical findings.
September 2002 in “Oncology Times” This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.
15 citations
,
January 2015 in “Analytical Methods” Method accurately measures finasteride in tablets using finasteride-BSA interaction.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly”
December 2023 in “International Journal of Pharmaceutics” This study developed innovative silica/natural polysaccharide hybrid nanoparticles encapsulating plant-derived 5-alpha-reductase inhibitors, reporting effective controlled release at hair follicle pH and lower cytotoxicity, suggesting a promising delivery system for antiandrogenic treatments.
2 citations
,
January 2011 This study developed and validated a UV spectrophotometric method for accurately measuring finasteride and tamsulosin in solutions and tablets, demonstrating good sensitivity and precision.
January 2004 in “Zhongguo xin yao zazhi” This study found that domestic finasteride tablets are bioequivalent to reference tablets, showing similar pharmacokinetic parameters and relative bioavailability.
November 2024 in “Journal of the American Academy of Dermatology” 2 citations
,
January 2013 in “Iraqi journal of Medical Sciences” This study concluded that domestic and imported finasteride tablets are bioequivalent, showing no significant differences in pharmacokinetic parameters among healthy volunteers.
1 citations
,
March 2013 in “The European Journal of Contraception & Reproductive Health Care” This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.
13 citations
,
May 2006 in “Annals of Saudi Medicine” The researchers reported substantial discrepancies in prescribing information between generic drugs marketed in Saudi Arabia and standard references, indicating a need for regulatory improvements to ensure accuracy and patient safety.
November 2025 in “Journal of Investigative Dermatology”
1 citations
,
January 2005 in “Side effects of drugs annual” This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.
May 2026 in “Drug Delivery” This study introduces a co-design framework using finite element analysis to optimize separable bubble microneedles, demonstrating enhanced transdermal and sublingual drug delivery in preclinical models. In vivo results showed faster hair regrowth and glucose lowering in animals, indicating potential improvements over traditional methods.
March 2017 in “Drug delivery letters” Dr. Jia-You Fang is a highly experienced researcher in drug delivery and related fields, with numerous publications and international collaborations.
This review highlights that certain plant species, like Glycyrrhiza inflata and rosemary, show potential in treating skin diseases such as rosacea and alopecia, but emphasizes the need for more clinical studies to validate these findings.
May 2023 in “Frontiers in Veterinary Science” This collection of articles explores advancements in reproductive technologies for domestic dogs and cats, highlighting improvements like finasteride treatment for BPH in dogs and a rapid freezing method for cat sperm that enhance fertility preservation and genetic resource banking.
24 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Adalimumab improved folliculitis decalvans in most patients.
January 2025 in “International Journal of Advancement in Life Sciences Research” In this cross-sectional study at a hospital in Nandyala, researchers identified nine drugs with potential new uses, noting that Aspirin and Dapagliflozin were most frequently repurposed, and observed changes in indications, dosage, and frequency, suggesting further clinical validation is needed for safety and efficacy.
117 citations
,
March 2013 in “Journal of the European Academy of Dermatology and Venereology” This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.